<p>新澤西州公共養老金基金 D 在最近向證券交易委員會提交的 13F 表格中披露，在第四季度購買了 Agios Pharmaceuticals, Inc.（NASDAQ:AGIO - 免費報告）的新頭寸。該公司購買了 47,414 股生物製藥公司的股票，價值約為 1,291,000 美元。新澤西州公共養老金基金 D 在最近的報告期末持有 Agios Pharmaceuticals 約 0.08% 的股份。</p>
<p>獲取 <strong>Agios Pharmaceuticals</strong> 的提醒：</p>
<p>其他幾家機構投資者也對該公司的持倉進行了調整。Creative Planning 在第三季度將其在 Agios Pharmaceuticals 的股份增加了 2.2%。Creative Planning 目前擁有 13,119 股生物製藥公司的股票，價值為 527,000 美元，此前在上個季度又購買了 280 股。Assetmark Inc.在第四季度將其在 Agios Pharmaceuticals 的股份增加了 37.9%。Assetmark Inc.目前擁有 1,317 股生物製藥公司的股票，價值為 36,000 美元，此前在上個季度又購買了 362 股。製造商人壽保險公司在第二季度將其在 Agios Pharmaceuticals 的持股增加了 0.4%。製造商人壽保險公司目前擁有 132,083 股生物製藥公司的股票，價值為 4,393,000 美元，此前在上個季度又購買了 512 股。未來資產全球投資有限公司在第四季度將其在 Agios Pharmaceuticals 的持股增加了 26.2%。未來資產全球投資有限公司目前擁有 2,834 股生物製藥公司的股票，價值為 77,000 美元，此前在上個季度又購買了 588 股。最後，加拿大人壽保險公司在第三季度將其在 Agios Pharmaceuticals 的持股增加了 3.4%。加拿大人壽保險公司目前擁有 20,325 股生物製藥公司的股票，價值為 796,000 美元，此前在上個季度又購買了 662 股。</p>
<h2>Agios Pharmaceuticals 股票表現</h2>
<p>AGIO 股票週一開盤價為 27.79 美元。該公司的 50 日移動平均價格為 29.70 美元，200 日移動平均價格為 30.59 美元。該股票的市值為 16.5 億美元，市盈率為-3.83，貝塔值為 0.58。Agios Pharmaceuticals, Inc.的 52 周低點為 22.24 美元，52 周高點為 46.00 美元。</p>
<p>Agios Pharmaceuticals（NASDAQ:AGIO - 獲取免費報告）最近於 4 月 29 日（星期三）發佈了季度財報。該生物製藥公司報告本季度每股收益為（1.69 美元），超出分析師一致預期的（1.81 美元）0.12 美元。Agios Pharmaceuticals 的股本回報率為-34.11%，淨利潤率為-639.84%。該公司本季度的收入為 2075 萬美元，而一致預期為 1330 萬美元。與去年同期相比，該公司的季度收入增長了 137.7%。整體來看，賣方分析師預測 Agios Pharmaceuticals, Inc.在本財年將發佈-6.19 的每股收益。</p>
<h2>華爾街分析師觀點</h2>
<p>AGIO 已成為幾份研究報告的主題。花旗集團在 3 月 5 日的研究報告中將 Agios Pharmaceuticals 的目標價從 38.00 美元上調至 46.00 美元，並給予該公司 “買入” 評級。高盛集團在 4 月 1 日的研究報告中將 Agios Pharmaceuticals 的目標價從 28.00 美元上調至 32.00 美元，並給予該公司 “中性” 評級。Wall Street Zen 在 3 月 22 日的研究報告中將 Agios Pharmaceuticals 的評級從 “賣出” 上調至 “持有”。HC Wainwright 在 4 月 20 日的研究報告中將 Agios Pharmaceuticals 的目標價從 65.00 美元下調至 50.00 美元，並對該股票給予 “買入” 評級。最後，Weiss Ratings 在 3 月 27 日的報告中重申了對 Agios Pharmaceuticals 股票的 “賣出（d）” 評級。六位股票研究分析師對該股票給予了買入評級，四位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “持有”，平均目標價為 41.56 美元。</p>
<p><strong>查看我們關於 Agios Pharmaceuticals 的最新研究報告</strong></p>
<h2>Agios Pharmaceuticals 的內部交易</h2>
<p>在其他新聞中，內部人士 Tsveta Milanova 於 4 月 2 日（星期四）出售了 3,262 股公司的股票。該股票以平均價格 34.71 美元出售，總價值為 113,224.02 美元。出售後，內部人士直接持有該公司 46,829 股股票，價值為 1,625,434.59 美元。此次交易使其持股減少了 6.51%。該出售在向 SEC 提交的文件中披露，文件可在 SEC 網站上獲取。該交易是在預先安排的 10b5-1 交易計劃下執行的。出售是為了覆蓋與股權獎勵歸屬相關的税款扣繳義務。此外，內部人士 James William Burns 於 4 月 2 日（星期四）出售了 3,280 股公司的股票。該股票以平均價格 34.71 美元出售，總價值為 113,848.80 美元。出售完成後，內部人士持有該公司 49,306 股股票，價值約為 1,711,411.26 美元。此次交易代表其持股減少了 6.24%。有關此次出售的更多細節可在官方 SEC 披露中找到。該交易是在預先安排的 10b5-1 交易計劃下執行的。出售是為了覆蓋與股權獎勵歸屬相關的税款扣繳義務。在上個季度，內部人士出售了價值 520,405 美元的 15,582 股公司股票。內部人士持有公司股票的 5.40%。</p>
<h2>關於 Agios Pharmaceuticals</h2>
<p>（免費報告）</p>
<p>Agios Pharmaceuticals, Inc 是一家生物製藥公司，成立於 2008 年，源於 Dana-Farber 癌症研究所和 Broad Institute 的研究。公司總部位於馬薩諸塞州劍橋，Agios 專注於理解和靶向細胞代謝，以開發針對癌症和罕見遺傳疾病的新療法。公司的科學平台整合了基因組發現、代謝譜分析和精準醫學的方法，以識別和推進能夠糾正或利用代謝功能障礙的小分子候選藥物。</p>
<p>Agios 的主要產品是針對特定癌症突變的 IDH（異檸檬酸脱氫酶）抑制劑。</p>
<h2>另見</h2>
<ul>
<li>五隻我們認為比 Agios Pharmaceuticals 更好的股票</li>
<li>超越 NVIDIA：強勁勢頭的 AI 相關投資</li>
<li>量子財報季正在升温——關注兩大主要參與者</li>
<li>Flutter 在財報後看到提振，FanDuel 顯示覆蘇跡象</li>
<li>3 只醫療保健股票將從這項重大法案中受益</li>
</ul>
<p><strong>想看看其他對 AGIO 感興趣的對沖基金持有什麼嗎？</strong> 請訪問 HoldingsChannel.com，獲取 Agios Pharmaceuticals, Inc.（NASDAQ:AGIO - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdJTw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Agios Pharmaceuticals 嗎？</h2>
<p>在考慮 Agios Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Agios Pharmaceuticals 並不在名單上。</p>
<p>雖然 Agios Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Agios制藥

<p>新澤西州公共養老金基金 D 在第四季度收購了 47,414 股 Agios Pharmaceuticals, Inc.（納斯達克代碼：AGIO），價值約為 129 萬美元。其他機構投資者也調整了在該公司的持倉。Agios Pharmaceuticals 報告的季度收入為 2075 萬美元，超出預期，且每股收益為負值（$1.69）。分析師對該股票的評級不一，平均目標價為 41.56 美元。內部人士 Tsveta Milanova 最近出售了 3,262 股，減少了其持股比例 6.51%</p>

<p>State of New Jersey Common Pension Fund D bought a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm bought 47,414 shares of the biopharmaceutical company's stock, valued at approximately $1,291,000. State of New Jersey Common Pension Fund D owned approximately 0.08% of Agios Pharmaceuticals at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>新澤西州公共養老金基金 D 在最近向證券交易委員會提交的 13F 表格中披露，在第四季度購買了 Agios Pharmaceuticals, Inc.（NASDAQ:AGIO - 免費報告）的新頭寸。該公司購買了 47,414 股生物製藥公司的股票，價值約為 1,291,000 美元。新澤西州公共養老金基金 D 在最近的報告期末持有 Agios Pharmaceuticals 約 0.08% 的股份。</p>
</div><p>Get <strong>Agios Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Agios Pharmaceuticals</strong> 的提醒：</p>
</div><p>Several other institutional investors have also made changes to their positions in the company. Creative Planning increased its position in shares of Agios Pharmaceuticals by 2.2% in the third quarter. Creative Planning now owns 13,119 shares of the biopharmaceutical company's stock worth $527,000 after acquiring an additional 280 shares in the last quarter. Assetmark Inc. raised its position in Agios Pharmaceuticals by 37.9% during the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company's stock valued at $36,000 after acquiring an additional 362 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Agios Pharmaceuticals by 0.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 132,083 shares of the biopharmaceutical company's stock worth $4,393,000 after purchasing an additional 512 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Agios Pharmaceuticals by 26.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,834 shares of the biopharmaceutical company's stock valued at $77,000 after purchasing an additional 588 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co grew its holdings in Agios Pharmaceuticals by 3.4% during the third quarter. CANADA LIFE ASSURANCE Co now owns 20,325 shares of the biopharmaceutical company's stock valued at $796,000 after purchasing an additional 662 shares during the last quarter.</p>
<div class="lb-trans"><p>其他幾家機構投資者也對該公司的持倉進行了調整。Creative Planning 在第三季度將其在 Agios Pharmaceuticals 的股份增加了 2.2%。Creative Planning 目前擁有 13,119 股生物製藥公司的股票，價值為 527,000 美元，此前在上個季度又購買了 280 股。Assetmark Inc.在第四季度將其在 Agios Pharmaceuticals 的股份增加了 37.9%。Assetmark Inc.目前擁有 1,317 股生物製藥公司的股票，價值為 36,000 美元，此前在上個季度又購買了 362 股。製造商人壽保險公司在第二季度將其在 Agios Pharmaceuticals 的持股增加了 0.4%。製造商人壽保險公司目前擁有 132,083 股生物製藥公司的股票，價值為 4,393,000 美元，此前在上個季度又購買了 512 股。未來資產全球投資有限公司在第四季度將其在 Agios Pharmaceuticals 的持股增加了 26.2%。未來資產全球投資有限公司目前擁有 2,834 股生物製藥公司的股票，價值為 77,000 美元，此前在上個季度又購買了 588 股。最後，加拿大人壽保險公司在第三季度將其在 Agios Pharmaceuticals 的持股增加了 3.4%。加拿大人壽保險公司目前擁有 20,325 股生物製藥公司的股票，價值為 796,000 美元，此前在上個季度又購買了 662 股。</p>
</div><h2>Agios Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Agios Pharmaceuticals 股票表現</h2>
</div><p>Shares of AGIO stock opened at $27.79 on Monday. The firm's 50 day moving average price is $29.70 and its two-hundred day moving average price is $30.59. The stock has a market cap of $1.65 billion, a PE ratio of -3.83 and a beta of 0.58. Agios Pharmaceuticals, Inc. has a 52-week low of $22.24 and a 52-week high of $46.00.</p>
<div class="lb-trans"><p>AGIO 股票週一開盤價為 27.79 美元。該公司的 50 日移動平均價格為 29.70 美元，200 日移動平均價格為 30.59 美元。該股票的市值為 16.5 億美元，市盈率為-3.83，貝塔值為 0.58。Agios Pharmaceuticals, Inc.的 52 周低點為 22.24 美元，52 周高點為 46.00 美元。</p>
</div><p>Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) EPS for the quarter, beating analysts' consensus estimates of ($1.81) by $0.12. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The business had revenue of $20.75 million during the quarter, compared to the consensus estimate of $13.30 million. The company's quarterly revenue was up 137.7% compared to the same quarter last year. As a group, sell-side analysts predict that Agios Pharmaceuticals, Inc. will post -6.19 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Agios Pharmaceuticals（NASDAQ:AGIO - 獲取免費報告）最近於 4 月 29 日（星期三）發佈了季度財報。該生物製藥公司報告本季度每股收益為（1.69 美元），超出分析師一致預期的（1.81 美元）0.12 美元。Agios Pharmaceuticals 的股本回報率為-34.11%，淨利潤率為-639.84%。該公司本季度的收入為 2075 萬美元，而一致預期為 1330 萬美元。與去年同期相比，該公司的季度收入增長了 137.7%。整體來看，賣方分析師預測 Agios Pharmaceuticals, Inc.在本財年將發佈-6.19 的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>AGIO has been the subject of several research reports. Citigroup increased their price objective on Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, March 5th. The Goldman Sachs Group upped their target price on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a &#34;neutral&#34; rating in a research note on Wednesday, April 1st. Wall Street Zen upgraded Agios Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Sunday, March 22nd. HC Wainwright lowered their price target on Agios Pharmaceuticals from $65.00 to $50.00 and set a &#34;buy&#34; rating on the stock in a research report on Monday, April 20th. Finally, Weiss Ratings restated a &#34;sell (d)&#34; rating on shares of Agios Pharmaceuticals in a report on Friday, March 27th. Six equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of &#34;Hold&#34; and an average target price of $41.56.</p>
<div class="lb-trans"><p>AGIO 已成為幾份研究報告的主題。花旗集團在 3 月 5 日的研究報告中將 Agios Pharmaceuticals 的目標價從 38.00 美元上調至 46.00 美元，並給予該公司 “買入” 評級。高盛集團在 4 月 1 日的研究報告中將 Agios Pharmaceuticals 的目標價從 28.00 美元上調至 32.00 美元，並給予該公司 “中性” 評級。Wall Street Zen 在 3 月 22 日的研究報告中將 Agios Pharmaceuticals 的評級從 “賣出” 上調至 “持有”。HC Wainwright 在 4 月 20 日的研究報告中將 Agios Pharmaceuticals 的目標價從 65.00 美元下調至 50.00 美元，並對該股票給予 “買入” 評級。最後，Weiss Ratings 在 3 月 27 日的報告中重申了對 Agios Pharmaceuticals 股票的 “賣出（d）” 評級。六位股票研究分析師對該股票給予了買入評級，四位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “持有”，平均目標價為 41.56 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Agios Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Agios Pharmaceuticals 的最新研究報告</strong></p>
</div><h2>Insider Transactions at Agios Pharmaceuticals</h2>
<div class="lb-trans"><h2>Agios Pharmaceuticals 的內部交易</h2>
</div><p>In other news, insider Tsveta Milanova sold 3,262 shares of the business's stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total value of $113,224.02. Following the sale, the insider directly owned 46,829 shares in the company, valued at $1,625,434.59. The trade was a 6.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James William Burns sold 3,280 shares of the business's stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total value of $113,848.80. Following the completion of the sale, the insider owned 49,306 shares in the company, valued at approximately $1,711,411.26. This trade represents a 6.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 15,582 shares of company stock valued at $520,405. Insiders own 5.40% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，內部人士 Tsveta Milanova 於 4 月 2 日（星期四）出售了 3,262 股公司的股票。該股票以平均價格 34.71 美元出售，總價值為 113,224.02 美元。出售後，內部人士直接持有該公司 46,829 股股票，價值為 1,625,434.59 美元。此次交易使其持股減少了 6.51%。該出售在向 SEC 提交的文件中披露，文件可在 SEC 網站上獲取。該交易是在預先安排的 10b5-1 交易計劃下執行的。出售是為了覆蓋與股權獎勵歸屬相關的税款扣繳義務。此外，內部人士 James William Burns 於 4 月 2 日（星期四）出售了 3,280 股公司的股票。該股票以平均價格 34.71 美元出售，總價值為 113,848.80 美元。出售完成後，內部人士持有該公司 49,306 股股票，價值約為 1,711,411.26 美元。此次交易代表其持股減少了 6.24%。有關此次出售的更多細節可在官方 SEC 披露中找到。該交易是在預先安排的 10b5-1 交易計劃下執行的。出售是為了覆蓋與股權獎勵歸屬相關的税款扣繳義務。在上個季度，內部人士出售了價值 520,405 美元的 15,582 股公司股票。內部人士持有公司股票的 5.40%。</p>
</div><h2>About Agios Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Agios Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.</p>
<div class="lb-trans"><p>Agios Pharmaceuticals, Inc 是一家生物製藥公司，成立於 2008 年，源於 Dana-Farber 癌症研究所和 Broad Institute 的研究。公司總部位於馬薩諸塞州劍橋，Agios 專注於理解和靶向細胞代謝，以開發針對癌症和罕見遺傳疾病的新療法。公司的科學平台整合了基因組發現、代謝譜分析和精準醫學的方法，以識別和推進能夠糾正或利用代謝功能障礙的小分子候選藥物。</p>
</div><p>Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.</p>
<div class="lb-trans"><p>Agios 的主要產品是針對特定癌症突變的 IDH（異檸檬酸脱氫酶）抑制劑。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Agios Pharmaceuticals</li>
<li>Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum</li>
<li>Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players</li>
<li>Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery</li>
<li>3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Agios Pharmaceuticals 更好的股票</li>
<li>超越 NVIDIA：強勁勢頭的 AI 相關投資</li>
<li>量子財報季正在升温——關注兩大主要參與者</li>
<li>Flutter 在財報後看到提振，FanDuel 顯示覆蘇跡象</li>
<li>3 只醫療保健股票將從這項重大法案中受益</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding AGIO?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 AGIO 感興趣的對沖基金持有什麼嗎？</strong> 請訪問 HoldingsChannel.com，獲取 Agios Pharmaceuticals, Inc.（NASDAQ:AGIO - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdJTw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AGIO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Agios Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Agios Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Agios Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Agios Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Agios Pharmaceuticals 並不在名單上。</p>
</div><p>While Agios Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Agios Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

47,414 Shares in Agios Pharmaceuticals, Inc. $AGIO Acquired by State of New Jersey Common Pension Fund D

Market Beat

新澤西州普通養老金基金 D 收購了 Agios 製藥公司 47,414 股股票